About Alimera Sciences (ALIM)
Alimera Sciences, Inc. is a commercial-stage global pharmaceutical company. The Company is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for no... Read more
- USD5.60
- USD5.60
- USD5.56
- USD5.65
- 1.30%
- 90M
- 1.34M
- 183.84k
- 292M
- 2.61
- 67.90%
Stock News
4 hours ago
1 Wall Street Analyst Thinks Tesla Stock Is Going to $258. Is It a Buy After a Post-Earnings Pullback?
Yahoo
6 hours ago
Warren Buffett Is in a Selling Mood. What’s Next?
Yahoo
6 hours ago
Weekly Market Outlook: Central Banks And U.S. Earnings. Will The BoJ Hike Rates?
SeekingAlpha
yesterday
Ackman’s Pershing Square USA says IPO is still happening, despite NYSE delay notice
MarketWatch
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
